Giovanni Vitale

Prof. Giovanni Vitale

Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Via Zucchi 18, 20095 Cusano Milanino (MI), Italy
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Open access
CFClaudio Franceschi
Claudio Franceschi
PGPaolo Garagnani
Paolo Garagnani
Giovanni VitaleGiovanni Vitale
Giovanni Vitale
MCMiriam Capri
Miriam Capri
SSStefano Salvioli
Stefano Salvioli
'Inflammaging' refers to the chronic, low-grade inflammation that characterizes aging. Inflammaging is macrophage centered, involves several tissues and organs, including the gut microbiota, and is characterized by a complex balance between pro- and anti-inflammatory responses. Based on literature data, we argue that the major source of inflammatory stimuli is represented by endogenous/self, misplaced, or altered molecules resulting from damaged and/or dead cells and organelles (cell debris), recognized by receptors of the innate immune system. While their production is physiological and increases with age, their disposal by the proteasome via autophagy and/or mitophagy progressively declines. This 'autoreactive/autoimmune' process fuels the onset or progression of chronic diseases that can accelerate and propagate the aging process locally and systemically. Consequently, inflammaging can be considered a major target for antiaging strategies.

12 September 2012 in Aging Cell
Verified
Journal Article
Open access
PDF file
PGPaolo Garagnani
Paolo Garagnani
MBMaria Giulia Bacalini
Maria Giulia Bacalini
CPChiara Pirazzini
Chiara Pirazzini
Davide GoriDavide Gori
Davide Gori
CGCristina Giuliani
Cristina Giuliani
CFClaudio Franceschi
Claudio Franceschi
Summary: The discovery of biomarkers able to predict biological age of individuals is a crucial goal in aging research. Recently, researchers' attention has turn toward epigenetic markers of aging. Using the Illumina Infinium HumanMethylation450 BeadChip on whole blood DNA from a small cohort of 64 subjects of different ages, we identified 3 regions, the CpG islands of ELOVL2, FHL2, and PENK genes, whose methylation level strongly correlates with age. These results were confirmed by the Sequenom's EpiTYPER assay on a larger cohort of 501 subjects from 9 to 99 years, including 7 cord blood samples. Among the 3 genes, ELOVL2 shows a progressive increase in methylation that begins since the very first stage of life (Spearman's correlation coefficient = 0.92) and appears to be a very promising biomarker of aging.

26 February 2013 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
Giovanni VitaleGiovanni Vitale
Giovanni Vitale
SSStefano Salvioli
Stefano Salvioli
CFClaudio Franceschi
Claudio Franceschi

1 April 2004 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Annamaria ColaoAnnamaria Colao
Annamaria Colao
Giovanni VitaleGiovanni Vitale
Giovanni Vitale
PCPaolo Cappabianca
Paolo Cappabianca
FBFrancesco Briganti
Francesco Briganti
ACAntonio Ciccarelli
Antonio Ciccarelli
GLGaetano Lombardi
Gaetano Lombardi
The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor shrinkage, restoration of pituitary function, and semen alterations was prospectively investigated in 41 men with macro- (age 17–70 yr) and 10 with microprolactinoma (age 18–53 yr). Fifty-one age-matched men served as controls for semen analysis. At study entry, of the 41 patients with macroprolactinoma, 17 (41.4%) had visual field defects, 14 (34.1%) had headache, eight (19.5%) had galactorrhea, 22 (53.6%) had hypopituitarism apart from hypogonadism, and 30 (73.2%) had low testosterone levels; of the 10 patients with microprolactinoma, none had visual field defects, galactorrhea, or hypopituitarism apart from hypogonadism, two had headache (20%), and five had low testosterone levels (50%; P = 0.3). After 24 months of therapy, 1) PRL levels normalized in 31 patients with macro- (75.6%) and in eight with microprolactinoma (80%; P = 0.9), and galactorrhea disappeared in all patients; 2) maximal tumor diameter reduced by 73.7 ± 22.6% in macro- and 72.8 ± 28.3% in microprolactinomas (P = 0.91), and 15 macro- (30%) and seven microprolactinomas (46.7%; P = 0.37) disappeared; 3) visual field defects disappeared in 15 (75%) patients with macroprolactinoma, and headache disappeared in 15 (83%) patients with macro- and in one with microprolactinoma (50%); 4) GH secretion recovered in 62.5% and ACTH secretion in 60% of patients; 5) testosterone levels normalized in 25 patients with macro- (60.9%) and six with microprolactinoma (60%) after 6 months, and 20 patients required testosterone or gonadotropin replacement (in 14 or six patients, respectively); and 6) sperm volume and count normalized in all patients who normalized testosterone levels, whereas motility normalized in more than 80%. Cabergoline therapy was well tolerated; only 4.5% of patients had side effects at high doses. These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas.

27 June 2018 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Closed access
PDF file
MCMaria Conte
Maria Conte
RORita Ostan
Rita Ostan
CFCristina Fabbri
Cristina Fabbri
ASAurelia Santoro
Aurelia Santoro
GGGiulia Guidarelli
Giulia Guidarelli
SSStefano Salvioli
Stefano Salvioli
Mitochondrial stress elicits the production of stress response molecules indicated as mitokines, including fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), and humanin (HN). Many diseases are characterized by progressive mitochondrial dysfunction with alterations of mitokine secretion. It is still controversial whether healthy aging and extreme longevity are accompanied by an altered production of mitokines. We analyzed FGF21, HN, and GDF15 plasma levels in 693 subjects aged from 21 to 113 years, and the association of these mitokines with parameters of health status. FGF21, HN, and GDF15 resulted increased in old age, with the highest levels found in centenarians. These molecules are associated with worsened parameters (such as handgrip strength, insulin sensitivity, triglycerides), particularly in 70-year-old persons, and their levels are inversely correlated with survival in the oldest subjects. Considering the positive biological effect of these molecules, our results can be interpreted in the framework of the hormetic paradigm as an attempt of the cells/tissues to cope with a stress that can have beneficial or detrimental effects depending on its intensity. Finally, persons with Down Syndrome (characterized by accelerated aging) have higher levels of GDF15 and HN with respect to their siblings, suggesting that these molecules, especially GDF15, could be considered markers of biological age.

25 August 2012 in AGE
Verified
Journal Article
Closed access
PDF file
gentilini davidegentilini davide
gentilini davide
DMDaniela Mari
Daniela Mari
DCDavide Castaldi
Davide Castaldi
Daniel RemondiniDaniel Remondini
Daniel Remondini
GOGiulia Ogliari
Giulia Ogliari
Giovanni VitaleGiovanni Vitale
Giovanni Vitale